Evaluation of the anticoagulant effect in Teneligliption in type 2 diabetic patients
Not Applicable
Recruiting
- Conditions
- Type 2 Diabetes Mellitus
- Registration Number
- JPRN-UMIN000011847
- Lead Sponsor
- Saitama Medical University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
Not provided
Exclusion Criteria
"1)Type I diabetes, the diabetes which arose according to the obstacle of the pancreas, or secondary diabetes patients (Cushing syndrome, tip hypertrophia, etc.) "2)Patient who corresponds to contraindications with the package leaflet of Teneligliptin "3)Patient with an excessive habitual drinking 4)Pregnant and breast-feeding "5)Patients judged by the research responsibility (assignment) doctor to be ineligible for some other reason
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method HbA1c, pre- and post-prandial(1,2hours)blood glucose, pre-and post-prandial(1,2hours)lipid, pre-and post-prandial(1,2hours)insulin, pre- and post-prandial(1,2hours)proinsulin, pre- and post-prandial(2hours)PAI-1
- Secondary Outcome Measures
Name Time Method